Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eilean Therapeutics Acquires Ness Therapeutics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eilean Therapeutics Acquires Ness Therapeutics

Ness’ non-clinical PTPN2 program has potential to improve the efficacy of cancer immunotherapy regimens.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing small molecule inhibitors to target resistance mechanisms in hematologic and solid malignancies, has acquired Ness Therapeutics Inc in an all-equity transaction.
 
Ness is developing PTPN2 inhibitors, providing an immuno-oncological therapy with an improved safety and tolerability profile.
 
Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), is ubiquitously expressed, primarily in hematopoietic and placental cells.  As a critical negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNγ. Thus, enhancing IFNγ sensing and signaling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens.
 
Ness’ lead molecules demonstrate sub-nanomolar PTPN2/PTPN1 inhibitory activity and outstanding > 1000-fold selectivity against all other phosphatases, exhibit high oral bioavailability and good safety. In addition, lead inhibitors induce tumor cells’ susceptibility to IFNγ and suppress their growth with a high efficacy.

Related News

Don’t miss Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics